The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
Abstract
Purpose: Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but progression invariably occurs. We investigated the efficacy and safety of alectinib, a potent and selective ALK inhibitor with excellent CNS penetration, in patients with crizotinib-refractory ALK-positive NSCLC. Patients and Methods: Alectinib 600 mg was administered orally twice daily. The primary end point was objective response rate (ORR) by central independent review committee (IRC). Results: Of the 138 patients treated, 84 patients (61%) had CNS metastases at baseline, and 122 were response evaluable (RE) by IRC. ORR by IRC was 50% (95% CI, 41% to 59%), and the median duration of response (DOR) was 11.2 months (95% CI, 9.6 months to not reached). In 96 patients (79%) previously treated with chemotherapy, the ORR was 45% (95% CI, 35% to 55%). Median IRC-assessed progression-free survival for all 138 patients was 8.9 months (95% CI, 5.6 to 11.3 months). CNS disease control rate was 83% (95% CI, 74% to 91%), and the median CNS DOR was 10.3 months (95% CI, 7.6 to 11.2 months). CNS ORR in 35 patients with baseline measurable CNS lesions was 57% (95% CI, 39% to 74%). Of the 23 patients with baseline CNS metastases (measurable or nonmeasurable) and no prior radiation, 10 (43%) had a complete CNS response. At 12 months, the cumulative CNS progression rate (24.8%) was lower than the cumulative non-CNS progression rate (33.2%) for all patients. Common adverse events were constipation (33%), fatigue (26%), and peripheral edema (25%); most were grade 1 to 2. Conclusion: Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Self-citationCrizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citationCeritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Self-citationCamidge, D. R., Bang, Y.-J., Kwak, E. L., Iafrate, A. J., Varella-Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S.-H. I., Kim, D.-W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,268
Self-citationShaw, A. T., Yeap, B. Y., Solomon, B. J., Riely, G. J., Gainor, J., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S.-H. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 899
Self-citationAcquired resistance to TKIs in solid tumours: learning from lung cancer
Camidge, D. R., Pao, W., & Sequist, L. V. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.104 · Cited by 862 · cited 1×
“Any cause, in $ 10% Patients Constipation 39 (28) 6 (4) 0 0 45 (33) Fatigue 26 (19) 8 (6) 2 (1) 0 36 (26) Peripheral edema 27 (20) 6 (4) 1 (1) 0 34 (25) Myalgia 25 (18) 5 (4) 1 (1) 0 31 (23) Asthenia 16 (12) 8 (6) 1 (1) 0 25 (18) Headache 16 (12) 4 (3) 2 (1) 0 22 (16) Cough 15 (11) 4 (3) 0 0 19 (14) Dyspnea 8 (6) 5 (4…”
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A. A., West, H. L., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 698
Self-citationCH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N., & Aoki, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.004 · Cited by 636
Costa, D. B., Shaw, A. T., Ou, S.-H. I., Solomon, B. J., Riely, G. J., Ahn, M.-J., Zhou, C., Shreeve, S. M., Selaru, P., Polli, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0539 · Cited by 599
Self-citationCSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Costa, D. B., Kobayashi, S., Pandya, S. S., Yeo, W.-L., Shen, Z., Tan, W., & Wilner, K. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1313 · Cited by 596
Seto, T., Kiura, K., Nishio, M., Nakagawa, K., Maemondo, M., Inoue, A., Hida, T., Yamamoto, N., Yoshioka, H., Harada, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70142-6 · Cited by 575
Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies
Lovly, C. M., & Shaw, A. T. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1610 · Cited by 273
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
Kodama, T., Hasegawa, M., Takanashi, K., Sakurai, Y., Kondoh, O., & Sakamoto, H. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2578-6 · Cited by 243
Ou, S.-H. I., Jänne, P. A., Bartlett, C. H., Tang, Y., Kim, D.-W., Otterson, G. A., Crinò, L., Selaru, P., Cohen, D. P., Clark, J. W., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt572 · Cited by 219
Self-citationSelective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
Kodama, T., Tsukaguchi, T., Yoshida, M., Kondoh, O., & Sakamoto, H. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.020 · Cited by 200
Khozin, S., Blumenthal, G. M., Zhang, L., Tang, S., Brower, M., Fox, E., Helms, W., Leong, R., Song, P., Pan, Y., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3157 · Cited by 190
Alectinib Shows Potent Antitumor Activity against RET -Rearranged Non–Small Cell Lung Cancer
Kodama, T., Tsukaguchi, T., Satoh, Y., Yoshida, M., Watanabe, Y., Kondoh, O., & Sakamoto, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0274 · Cited by 172
Gainor, J. F., Sherman, C. A., Willoughby, K., Logan, J., Kennedy, E., Brastianos, P. K., Chi, A. S., & Shaw, A. T. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000455 · Cited by 168
Kinoshita, K., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Hara, S., Ohwada, J., Miyagi, T., Kobayashi, T., Takanashi, K., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.021 · Cited by 164
Malik, S. M., Maher, V. E., Bijwaard, K. E., Becker, R. L., Zhang, L., Tang, S. W., Song, P., Liu, Q., Marathe, A., Gehrke, B. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3077 · Cited by 152
Kim, D. S., Ahn, M., Yang, P., Liu, X., Pas, T. M. D., Crinò, L., Lanzalone, S., Polli, A., & Shaw, A. T. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)33871-0 · Cited by 71
Self-citationOu, S. I., Sommers, K. R., Azada, M. C., & Garon, E. B. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0309 · Cited by 57
Self-citationShaw, A. T., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., Pas, T. M. D., Riely, G. J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu349.72 · Cited by 34
Self-citation
Cited by
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Self-citationNon–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Gainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo-Jack, I., Gadgeel, S., Schultz, K., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,148
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980
Self-citation
Metadata
- Authors
- Ou, S.-H. I., Ahn, J. S., De Petris, L., Govindan, R., Yang, J. C.-H., Hughes, B., Lena, H., Moro-Sibilot, D., Bearz, A., Ramirez, S. V., Mekhail, T., Spira, A., Bordogna, W., Balas, B., Morcos, P. N., Monnet, A., Zeaiter, A., & Kim, D.-W.
- Venue
- Journal of Clinical Oncology
- Published
- 2016-03-01
- Volume
- 34
- Issue
- 7
- Pages
- 661-668
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2174368583
- Cited by
- 580
- References
- 26
- FWCI
- 79.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.